[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-disease-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-disease-chronic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,76,101,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100630434","evaluation-of-the-hepatoprotective-effects-of-a-nutritional-supplement-in-patients-with-liver-disease-secondary-to-chronic-hepatitis-c-virus-infection-resqueti-study-100630434",false,"NCT07487623","Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).","Evaluation of the Hepatoprotective Effects of a Nutritional Supplement Containing Resveratrol, Quercetin, Taurine, Inulin, and Whey Protein on Biochemical, Molecular, and Clinical Markers in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).","RESQUETI","Inclusion Criteria:\n\nPatients with liver disease secondary to chronic hepatitis C virus infection who attend the outpatient Hepatitis Clinic of the Gastroenterology Department at Hospital Civil Fray Antonio Alcalde.\n\nChild-Pugh score \\\u003C 8 points. Age 18-69 years. Both sexes. Signed informed consent.\n\n\\-\n\nExclusion Criteria:\n\n* Patients with alcohol consumption within the past 6 months. Patients with a history of acute-on-chronic liver failure (ACLF). Patients with persistent hepatic encephalopathy. Patients unable to perform frailty assessments. Patients with refractory ascites. Patients with a history of hepatorenal syndrome. Patients with a history of hepatopulmonary syndrome. Patients with chronic kidney disease. Patients with autoimmune diseases. Patients with any type of cancer. Patients with dementia or other significant mental illnesses. Use of protein supplements or probiotics.","ALL","18 Years","69 Years",{"count":21,"type":22},26,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in patients with liver disease related to chronic hepatitis C infection.\n\nThe study will compare the investigational supplement with an active control (whey protein alone) to determine whether the combination formulation provides additional benefits on liver-related biomarkers and clinical assessment.\n\nParticipants will:\n\nTake the investigational supplement or active control daily for 12 weeks.\n\nAttend clinic visits every 4 weeks for laboratory testing and clinical evaluations.",[28,29],"Liver Disease Chronic","HEPATITIS C VIRUS CHRONIC INFECTION",[31,32,33,34,35,36,37,38],"liver disease chronic","hcv","resveratrol","quercetin","taurine","inulin","frailty","whey protein","RECRUITING","2026-03-17",{"date":42,"type":43},"2026-03-23","ACTUAL",{"date":45,"type":43},"2025-10-11",{"date":47,"type":22},"2026-05-15",{"name":49,"class":50},"University of Guadalajara","OTHER",2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100629372","validation-of-different-methods-for-hepquant-duo-blood-sample-collection-100629372","NCT07473817","Validation of Different Methods for HepQuant DuO® Blood Sample Collection","Inclusion Criteria:\n\n* adult healthy participant with no major comorbidities and lean body mass (BMI 18-25.5)\n* adult participant with all etiologies of parenchymal chronic liver disease or PBC or PSC with F2-F3 fibrosis or cirrhosis.\n\nExclusion Criteria:\n\n* under the age of 18\n* pregnancy\n* Unable to absorb orally administered cholate (examples could include underlying severe gastroparesis or having undergone extensive small bowel resection, conditions or post-operative state that could impair the absorption of the orally administered d4-cholate)\n* NPO (nothing through the mouth) status or those who are unable to ingest a thin liquid by mouth\n* for patients with cirrhosis, any hospital admission within 3 months of enrollment in the study.",true,{"count":60,"type":22},200,"OBSERVATIONAL","This is a study to see the agreement of blood samples collected through different means and tube types for the HepQuant DuO Test. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data from patients living with chronic liver disease and healthy adult volunteers. The study has up to 2 study visits at an outpatient clinic and can take up to 4 weeks for a participant to complete study. At these visits, participants will undergo a HepQuant DuO test and other standard lab tests. In addition, the study team will ask about a participant's experience with different blood sampling methods.",[64,28],"Healthy Adult Participants","NOT_YET_RECRUITING","2026-03-11",{"date":68,"type":43},"2026-03-16",{"date":70,"type":22},"2026-04-20",{"date":72,"type":22},"2027-04-20",{"name":74,"class":75},"HepQuant, LLC","INDUSTRY",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":51},"100455085","hephospital-a-pilot-trial-of-a-hepatology-home-hospital-intervention-for-patients-with-advanced-liver-disease-100455085","NCT05205954","HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease","Inclusion Criteria:\n\n1. Adult patients ≥ 18 years old with diagnosis of cirrhosis based on histology, radiology, and\u002For elastography presenting to the emergency department or inpatient general medicine service\n2. Patients must have one of the following:\n\n   1. Ascites (requiring diuretics or serial large volume paracenteses)\n   2. Hepatic hydrothorax (requiring diuretics)\n   3. Hepatic encephalopathy (requiring medications)\n\nExclusion Criteria: All existing MGB home hospital criteria apply, with the following taking precedent for this specific condition\n\n1. History of solid organ transplantation\n2. On hemodialysis\n3. MELD score \\> 20\n4. Score \\\u003C10 on Simplified Animal Naming Test (S-ANT1)\n5. Current admission for hemodynamically significant GI bleeding or alcohol withdrawal\n6. Require routine administration of controlled substances\n7. Those deemed ineligible based on the MGH Home Hospital, inpatient medicine or hepatology clinician evaluation",{"count":83,"type":22},30,[25],"This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.",[87,88,89,28],"Cirrhosis","End Stage Liver DIsease","Liver Cirrhosis",[91,92],"Hospital at home","Home hospital","2025-07-21",{"date":95,"type":43},"2025-07-24",{"date":93,"type":43},{"date":98,"type":22},"2026-12-31",{"name":100,"class":50},"Massachusetts General Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100515962","liverpal-a-trial-of-inpatient-palliative-care-for-patients-with-advanced-liver-disease-100515962","NCT05998330","LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease","LiverPAL: A Randomized Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease","LiverPAL","Patient Inclusion Criteria:\n\n1. Hospitalized patient with a diagnosis of advanced liver disease, defined as cirrhosis with one of the following (new or ongoing) within the prior six months from date of consent:\n\n   * Ascites (requiring diuretics or serial large volume paracenteses)\n   * Spontaneous bacterial peritonitis\n   * Hepatic hydrothorax (requiring diuretics)\n   * Variceal bleed (with one or more occurrences)\n   * Overt hepatic encephalopathy (requiring medications)\n2. Ability to comprehend English\n\nPatient Exclusion Criteria:\n\n1. Prior history of liver transplantation\n2. Have uncontrolled hepatic encephalopathy, cognitive impairment, psychiatric disorder or other comorbid condition which the primary medical, hepatology, and\u002For transplant surgery teams believes prohibits the ability to provide informed consent\n3. Current or recent (within 5 years of receiving curative cancer treatment) history of extrahepatic malignancy (excluding non-melanoma skin cancer)\n4. Presence of hepatocellular carcinoma beyond Milan criteria\n5. Are already receiving hospice care\n6. Receive a score of \\\u003C10 on the Simplified Animal Naming Test\n\nCaregiver Inclusion Criteria\n\n1. Adult caregiver (≥ 18 years of age)\n2. A relative or friend identified by the patient upon whom the patient relies for help and who likely is to be present in-person during hospitalizations or clinic appointments, or willing to participate by phone\n3. Ability to comprehend English and can complete questionnaires\n\nCaregiver Exclusion Criteria\n\n1\\. Inability to comprehend English",{"count":60,"type":22},[25],"The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood, and serious illness communication. Palliative care is a medical specialty focused on lessening (or \"palliating\") symptoms and assisting in coping with serious illness.",[28,88,87,113,114],"Cirrhosis, Liver","Advanced Cirrhosis","2025-07-14",{"date":117,"type":43},"2025-07-17",{"date":119,"type":43},"2023-09-20",{"date":121,"type":22},"2027-07",{"name":100,"class":50},1,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":58,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":123},"100512712","albumin-catabolic-rate-measured-by-a-stable-isotope-100512712","NCT05956015","Albumin Catabolic Rate Measured by a Stable Isotope","Inclusion Criteria:\n\nHealthy volunteers:\n\n* males and females \\>= 40 years (to be more like the anticipated age of the liver patients)\n* good peripheral blood vessels\n* written informed consent\n\nPatients with liver cirrhosis:\n\n* known compensated liver cirrhosis with radiological or endoscopic signs of portal hypertension, such as varices, splenomegaly, or shunts.\n* written informed consent\n\nExclusion Criteria:\n\n* Planned surgical procedure within 3 months (due to possible blood loss i.e. loss of tracer)\n* Pregnancy at dosing\n* Phenylketonuria\n* Participating in other study with stable isotopes within 60 days.\n* Circumstance that causes the responsible researcher to assess the research person's participation as inappropriate","40 Years",{"count":132,"type":22},24,[25],"The goal of this physiological study is to compare albumin catabolic rate measured by a stable isotope labeled amino acid in healthy volunteers and in patients with liver disease. At steady state synthesis and catabolism or degradation are equal.\n\nThe primary questions it aims to answer are:\n\n* Is albumin catabolic rate lower in patients with liver disease?\n* Is albumin catabolic rate measured by stable isotopes in volunteers like historical controls measured by radio-iodinated albumin at the investigator's laboratory or elsewhere? Subjects will be given an oral dose of the deuterium labeled amino acid phenylalanine that will be incorporated by the liver in newly synthetized albumin molecules, and blood samples will be taken over 12 weeks to determine the catabolic rate of albumin.",[28],[137],"albumin catabolism","2023-07-23",{"date":140,"type":43},"2023-07-25",{"date":142,"type":22},"2023-08-28",{"date":144,"type":22},"2028-12-31",{"name":146,"class":50},"Ake Norberg"]